Menveo is a vaccine that protects against four types of meningococcal bacteria: groups A, C, W-135, and Y.
MENVEO is listed under Health Canada DIN 02563029. The product record and monograph below describe this formulation; the dose schedule comes from the Canadian Immunization Guide.
At a glance
Brand
MENVEO
DIN
02563029
Vaccine
Meningococcal A, C, W-135, Y oligosaccharide conjugate
Presentation
0.5 mL · solution (liquid) · intramuscular · 2 months and older
Live vaccine
No
Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with a healthcare professional.
Official sources
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
A listed product may not be stocked or publicly funded.
Before and after your vaccination
Bring your immunization record if you have one, so earlier doses can be checked.
Tell the healthcare professional about a serious reaction to a previous vaccine or an ingredient, and mention any health conditions or medicines that could affect your vaccination.
After the dose, stay where you can be observed for at least 15 minutes. Tell someone right away if you feel faint or develop symptoms of an allergic reaction.
Keep a record of the vaccine name, date and dose you received.
The details below are adapted from a Pharmasist patient handout linked to the same product monograph. The current Canadian Immunization Guide determines the dose schedules shown later.
What this vaccine helps prevent
Menveo is a vaccine that protects against four types of meningococcal bacteria: groups A, C, W-135, and Y.
These bacteria can cause serious, sometimes life-threatening infections such as meningitis and blood poisoning.
Menveo can be given to people from 2 months up to 55 years of age.
What to mention before a dose
Tell your healthcare professional if you or your child has ever had an allergic reaction to Menveo or to any vaccine containing a diphtheria-related protein.
Tell your healthcare professional if you or your child has a bleeding problem, such as hemophilia, or is taking blood-thinning medicine.
Tell your healthcare professional if you or your child has a weak immune system or takes medicine that affects the immune system.
Tell your healthcare professional if you or your child has ever fainted after getting a needle.
Tell your healthcare professional if you or your child has a history of Guillain-Barré syndrome, a nerve condition.
How it is given
A healthcare professional will give this vaccine as a shot into a muscle, usually in the thigh for infants or the upper arm for children, teens, and adults.
Depending on age, one to four doses are needed, spaced weeks to months apart, to build full protection.
Your healthcare professional will mix the powder and liquid components together right before giving the injection.
Important things to know
Severe allergic reactions can happen with any vaccine, though this is rare.
This vaccine contains a diphtheria-related protein but does not protect against diphtheria — routine diphtheria vaccines are still needed.
If you or your child is being treated with a medicine that blocks part of the immune system, such as eculizumab, protection against meningococcal disease may still be incomplete even after vaccination.
Effects you may notice
Soreness, redness, or firmness where the shot was given.
Fussiness or crying, especially in babies.
Sleepiness.
Changes in eating habits in infants.
Headache.
Muscle aches or joint pain.
Feeling generally unwell or tired.
Nausea or vomiting.
Mild fever or chills.
A mild rash.
When to contact a healthcare professional
If you or your child does not feel well after the shot.
If swelling at the injection site becomes very large or spreads down the whole arm or leg.
If a fever is high or does not go away.
If dizziness, ringing in the ears, or balance problems occur.
When to get emergency help
Trouble breathing, wheezing, or swelling of the lips, mouth, throat, hands, feet, or ankles.
A sudden drop in blood pressure, fainting, or loss of consciousness.
Hives or a widespread rash appearing quickly after the shot.
A seizure or sudden weakness or numbness in the face or limbs.
Other medicines and vaccines
Tell your healthcare professional about all medicines, vaccines, vitamins, and supplements you or your child are taking.
Menveo can usually be given at the same visit as many other vaccines, as long as they are given in different arms or legs.
Food and alcohol have no known effect on how this vaccine works, since it is given by injection rather than swallowed.
Key points to remember
You may feel dizzy or unwell for a short time after the shot — avoid driving or using machinery until you know how you feel.
This vaccine only protects against groups A, C, W-135, and Y meningococcal bacteria, not all causes of meningitis.
Tell your healthcare professional about any side effect, even ones not listed here.
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination. Public health recommendations may differ from a product monograph's authorized schedule.
Meningococcal ACYW — toddler dose at 12 to 23 months
1 dose
One dose of quadrivalent (Men-C-ACYW) conjugate vaccine at 12 to 23 months.
NACI (May 2026): all children 12 to 23 months of age should receive one dose of quadrivalent meningococcal conjugate (Men-C-ACYW) vaccine, replacing the Men-C-C toddler dose. A child who already had Men-C-C at 12 to 23 months is not revaccinated. MENQUADFI is authorized from 12 months, NIMENRIX from 6 weeks, MENVEO from 2 months.
Meningococcal ACYW — routine adolescent or adult, one dose
1 dose
One dose of Men-C-ACYW conjugate vaccine, routinely given at about 12 years of age.
Routine single adolescent dose regardless of infant or toddler history; also for adults with travel, occupational or outbreak indications.
Meningococcal ACYW — high-risk conditions, two doses
2 doses
Two doses 8 weeks apart for asplenia, complement deficiency, HIV and other high-risk conditions.
For people 12 months and older with no spleen or a spleen that does not work, complement or properdin deficiency (including eculizumab or ravulizumab treatment), HIV, or other high-risk conditions. Two doses at least 8 weeks apart (4 weeks if accelerated). A booster every 5 years while risk continues (every 3 years if first immunized under 7 years of age).
General information only. A suggested date is not an appointment or a prescription; a healthcare professional confirms what you need. Clinical rules reviewed on 2026-09-27.